AIM:To investigate the protective effect of hyperoside (Hyp) on Mycoplasma pneumoniae (MP) pneumonia (MPP) mice and the underlying regulatory mechanism.METHODS:BALB/c mice (n=40) were randomly divided into control group, model group, low-dose (12.5 mg/kg) Hyp group and high-dose (50 mg/kg) Hyp group.The MPP model was established using MP standard strains (MPFH) through nasal dripping.The treatment started on the second day, and the follow-up experiments were performed after 3 d.The lung histopathology were detected by HE staining.The levels of C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH) and MB isoenzyme of creatine kinase (CK-MB) in the serum, and the levels of reactive oxygen species (ROS), superoxide dismutase (SOD) and glutathione (GSH) in the lung tissues were measured by automatic biochemical analyzer.ELISA and Western blot were used to detect interleukine-1 beta (IL-1β), IL-6, IL-18 and tumor necrosis factor-alpha (TNF-α) levels in the serum and lung tissues, respectively.The expression of NLRP3, ASC and caspase-1 at mRNA and protein levels was evaluated by RT-qPCR and Western blot.RESULTS:Compared with control group, the inflammation and alveolar interstitial widening were observed in the lung tissues of model mice, and the CRP, ALT, AST, LDH and CK-MB levels were significantly up-regulated (P<0.05).The ROS level was increased, while SOD and GSH levels were significantly decreased (P<0.05).The levels of IL-1β, IL-6, IL-18 and TNF-α were markedly up-regulated (P<0.05).The protein expression of NLRP3, ASC and caspase-1 was also obviously increased (P<0.05) in model group.Compared with model group, the symptoms above were significantly relieved in Hyp group, and the effect of high-dose Hyp was more apparent than that of the low-dose one.CONCLUSION:Hyperoside suppresses the injury in MPP mice, which may be related to the inhibition of oxidative stress and NLRP3 inflammasome activation.

Objective:To explore the clinical effect of intravenous immunoglobulin combined with conventional therapy in the treatment of severe pneumonia in infants and children.Methods:Selected the January 2015 to April 2016 in our hospital for treatment of 88 cases of children with severe pneumonia were retrospectively analyzed,which 47 cases by routine treatment plus intravenous immunoglobulin protein (treatment group),41 cases of children only take routine therapy (control group),with a course of 2 weeks.Results:The symptoms of fever,dyspnea,cough,wheezing,pulmonary rales were improved faster in the treatment group than the control group (P＜0.05);after 2 weeks of treatment,IgG levels were significantly higher in the treatment group than the control group(P＜0.05);after 2 weeks of treatment,the serum IL-6 and TNF-α levels were significantly lower in the treatment group than the control group(P＜ 0.05);after 1 week of treatment,57.45％ of patients was cured in the treatment groups while only 34.15％ patients in the control group (P＜0.05).Conclusion:Intravenous immunoglobulin combined with conventional therapy in the treatment of infants with severe pneumonia can significantly improve the theraputic effect and enhance blood immunoglobulin levels.

Objective:To compare the efficacy and safety between WangShiBaoChiWan and mosapride in the treatment of functional dyspepsia (FD).Methods:From September 2019 to September 2020, patients with postprandial fullness and early satiation who met the Rome Ⅳ criteria for FD diagnosis were enrolled from 15 hospitals, including the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical College. The subjects were randomly divided into WangShiBaoChiWan (experimental) group and mosapride (control) group in the ratio of 1∶1. The treatment regimens were WangShiBaoChiWan+ mosapride simulator, WangShiBaoChiWan simulator+ mosapride, respectively with a treatment period of 2 weeks. The primary efficacy outcome was the improvement rates of main symptoms before and after treatment, the secondary efficacy primary efficacy outcome was the total clinical effective rate and the change of the single symptom score. And the safety indicator included adverse events. Independent sample t-test, paired t-test and chi-square test were used for statistical analysis. Results:A total of 251 FD patients were enrolled in the full analysis set, including 124 in the experimental group and 127 in the control group; 241 FD patients were in the per-protocol analysis set, including 117 in the experimental group and 124 in the control group. The analysis of per-protocol analysis set showed that the improvement rates of the main symptoms of the experimental group and the control group were (66±29)% and (60±30)%, respectively, and the difference was not statistically significant ( P>0.05). The improvement rate of the main symptoms of the experimental group reached 117% of that of the control group, which exceeded the expected non-inferiority standard of 80%. The total clinical effective rates of the experimental group and the control group were 76.07% (89/117) and 75.81% (94/124), respectively, and the difference was not statistically significant ( P>0.05). The results of full analysis set showed that the incidence of adverse events of the experimental group and the control group was 1.62% (2/124) and 1.57% (2/127), respectively, and the difference was not statistically significant ( P>0.05). There were no serious adverse events in the two groups. Conclusion:The improvement rate of the main symptoms of WangShiBaoChiWan is not inferior to that of mosapride in the treatment of FD, and it has good safety.

It is difficult to accurately distinguish pharyngitis caused by Group A Streptococcus(GAS) from other pathogens according to the clinical presentation alone, which cannot effectively guide the rational use of antimicrobials.The pharyngeal swab culture, rapid antigen detection test, nucleic acid test, and blood test can help definitively diagnose GAS pharyngitis.However, there are differences in different guidelines on who the laboratory test methods are intended for, interpretation of laboratory test results and so on.This article summarizes and analyses the laboratory diagnostic modalities and their characteristics, as well as recommendations for GAS pharyngitis in different guidelines to provide references for the clinical diagnosis, antimicrobial treatment, and further study of GAS pharyngitis.

Puerarin (Pue), known as a phytoestrogen, has salient bioactivities and is promising against cardiovascular diseases. This article summarizes the underlying molecular mechanisms of Pue in treating cardiovascular diseases, especially regulating the intracellular signal transduction, influencing ion channels, modulating the expression of microRNA, and impacting on the autophagy, which are mainly involved in the inflammatory signaling pathways, fatty acid/lipid metabolism, oxidative stress, apoptosis, and the like. The protective effect of Pue against cardiovascular diseases mainly involves attenuating the myocardial injury and decreasing the myocardial fibrosis, improving the myocardial ischemia/reperfusion injury, as well as inhibiting the myocardial hypertrophy and atherosclerosis. The molecular mechanisms of Pue's cardiovascular protective effects for the first time and comment on the state-of-the-art research methods and principles of Pue's regulation of small molecules were reviewed, so as to provide the rationale for its basic research and clinical applications.